The only way to improve cancer detection, prevention, and treatment is through research. People participating in research contribute to medical knowledge and have opportunity to receive cutting-edge care.
Addition of Pembrolizumab to Radiation Treatment for Newly Diagnosed Early Stage MSI-High Endometrial Cancer
Clinicaltrials.gov identifier:
NCT04214067
Study Contact Information:
Principal Investigator: Floor Backes
For additional information: Use the contacts listed per each study location.
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer
About the Study
The purpose of this study is to determine whether the addition of the agent, pembrolizumab (Keytruda) to radiation therapy is more effective than radiation therapy alone in reducing the risk of cancer recurrence in patients with newly diagnosed I-II endometrial cancer that is . NOTE: This study is no longer enrolling.
This study is no longer enrolling.
- This study is no longer enrolling.